TOKYO--(BUSINESS WIRE)--Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that Roche received the decision from the European Commission confirming that Hemlibra ® (emicizumab) , a ...
The National Institute for Health and Care Excellence (NICE) has published a final draft guidance recommending efanesoctocog alfa for treating and preventing bleeding episodes in people aged 2 years ...
Efanesoctocog alfa provides high sustained factor VIII activity by overcoming the von Willebrand factor–imposed half-life ceiling. The efficacy, safety, and pharmacokinetics of efanesoctocog alfa for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback